AgingResearch.News
Frontiers in Endocrinology

Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes

By Mizuki Gobaru, Nao Hasuzawa, Noboru Kurinami, Show 6 more authorsMasatoshi Nomura
Graphical abstract. Body recomposition after 1 year of treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), or GLP-1RA add-on to SGLT2i therapy…
Open the figure at full size
Graphical abstract. Body recomposition after 1 year of treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), or…Body recomposition after 1 year of treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), or GLP-1RA add-on to SGLT2i therapy (GLP-1-on-SGLT2i).Gobaru et al.
Cohort study of 148 peopleInterventions

12 months, independent replication, multicentre, registered UMIN000048469, declared no competing interests

Paper

The paper

Mizuki Gobaru, Nao Hasuzawa, Noboru Kurinami, Show 6 more authorsMasatoshi Nomura

Kurume University

Frontiers in Endocrinology, 27 Aug 2026

doi.org/10.3389/fendo.2026.1924744PubMed 42723833

More on GLP-1 receptor agonists